| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/070674370505001110 |
| P698 | PubMed publication ID | 16363464 |
| P2093 | author name string | Robert Miller | |
| Howard C Margolese | |||
| Lawrence Annable | |||
| Linda Beauclair | |||
| Theodore T Kolivakis | |||
| Guy Chouinard | |||
| P2860 | cites work | The effects of clozapine on tardive dyskinesia | Q28322745 |
| Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone | Q28369458 | ||
| Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group | Q28371928 | ||
| Two cases of risperidone-induced tardive dyskinesia and a review of the literature | Q28376866 | ||
| Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group | Q33178075 | ||
| Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia | Q34059501 | ||
| Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study | Q34088923 | ||
| Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. | Q34201539 | ||
| Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. | Q34246646 | ||
| Therapeutic strategies against tardive dyskinesia. Two decades of experience | Q34247317 | ||
| Ziprasidone, a new atypical antipsychotic drug | Q34278844 | ||
| Long-term effects of tetrabenazine in hyperkinetic movement disorders | Q34417087 | ||
| The emerging role of clozapine in the treatment of movement disorders | Q34434857 | ||
| Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III. | Q34464385 | ||
| Dosing and switching strategies for quetiapine fumarate | Q34575702 | ||
| Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group | Q34719739 | ||
| Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia | Q36495584 | ||
| Clozapine: new research on efficacy and mechanism of action | Q38362817 | ||
| Paradoxical response to dopamine agonists in tardive dyskinesia | Q39149963 | ||
| Factors related to tardive dyskinesia | Q39225030 | ||
| Tardive dyskinesia--reversible and persistent | Q39246141 | ||
| In Search of Treatment for Tardive Dyskinesia: Review of the Literature* | Q39259811 | ||
| Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine | Q39636429 | ||
| Neuroleptic withdrawal in schizophrenic patients. A review of the literature | Q40602444 | ||
| Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients | Q40779000 | ||
| Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction | Q40928089 | ||
| Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison | Q41044563 | ||
| Clozapine in tardive dyskinesia | Q41370034 | ||
| Clonazepam and phenobarbital in tardive dyskinesia | Q41473687 | ||
| Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients | Q41671806 | ||
| New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up | Q41703313 | ||
| Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone | Q41744286 | ||
| Extrapyramidal symptoms in patients treated with risperidone | Q42549335 | ||
| Extrapyramidal side effects with low-dose risperidone | Q42550050 | ||
| Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial | Q42550364 | ||
| A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group | Q42628400 | ||
| Risperidone and tardive dyskinesia: a case of blepharospasm | Q43508434 | ||
| Reduction of tardive dyskinesia with quetiapine | Q43588055 | ||
| Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine | Q43647924 | ||
| Quetiapine-related tardive dyskinesia | Q43752244 | ||
| Risperidone for tardive dyskinesia | Q43787451 | ||
| Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study | Q43790293 | ||
| Tardive dyskinesia and ziprasidone | Q44086854 | ||
| Rapid onset of tardive dyskinesia in Huntington disease with olanzapine | Q44097713 | ||
| Switching antipsychotic medications: general recommendations and switching to amisulpride | Q44118527 | ||
| Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain | Q44120358 | ||
| Catastrophic reactions induced by tetrabenazine | Q44159910 | ||
| A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia | Q44209608 | ||
| Olanzepine-induced tardive dyskinesia | Q44267670 | ||
| Clozapine and tardive dyskinesia | Q44336432 | ||
| Treatment-emergent tardive dyskinesia with quetiapine in mood disorders | Q44550801 | ||
| Ziprasidone-related tardive dyskinesia | Q44710973 | ||
| Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. | Q45333753 | ||
| Manual for the Extrapyramidal Symptom Rating Scale (ESRS). | Q50279993 | ||
| Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. | Q52008846 | ||
| Clozapine for tardive dyskinesia in adolescents. | Q52016855 | ||
| Clozapine-related tardive dyskinesia. | Q52025914 | ||
| Risperidone and tardive dyskinesia in organic psychosis. | Q53222413 | ||
| Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. | Q53360074 | ||
| Tardive dyskinesia associated with olanzapine. | Q54482033 | ||
| Rabbit syndrome treated with olanzapine. | Q55033782 | ||
| Risperidone-induced tardive dyskinesia and parkinsonism | Q57982354 | ||
| Use of Clonazepam in an Elderly Bipolar Patient with Tardive Dyskinesia: A Case Report | Q58155514 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| dyskinesia | Q629444 | ||
| P304 | page(s) | 703-714 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Canadian Journal of Psychiatry | Q5030253 |
| P1476 | title | Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia | |
| P478 | volume | 50 |
| Q46212807 | An adaptive role of TNFα in the regulation of striatal synapses |
| Q39396657 | Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy |
| Q56790555 | Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management |
| Q59460890 | Antipsychotikainduzierte tardive Syndrome |
| Q42348171 | Aripiprazole-induced Tardive Dyskinesia in 13 Years Old Girl Successfully Treated with Biperiden: A Case Report |
| Q86545334 | Association of the dopamine β-hydroxylase 19 bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia |
| Q46079565 | Atypical antipsychotic drugs have their merits |
| Q55059642 | Breakthrough drugs for the interface between psychiatry and neurology. |
| Q37460501 | Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature |
| Q47675010 | Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? |
| Q64940754 | Diagnosing Covariate Balance Across Levels of Right-Censoring, Before and After Applying Inverse Probability of Censoring Weights. |
| Q38545655 | Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials |
| Q39065466 | Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next? |
| Q36330858 | Estimating the optimal dynamic antipsychotic treatment regime: Evidence from the sequential multiple assignment randomized CATIE Schizophrenia Study |
| Q36816763 | High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature |
| Q53006399 | Interpreting the efficacy findings in the CATIE study: what clinicians should know. |
| Q36806137 | Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations |
| Q33612521 | Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II |
| Q24599912 | New and emerging treatments for symptomatic tardive dyskinesia |
| Q26852807 | Pharmacogenetics and outcome with antipsychotic drugs |
| Q38819771 | Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients |
| Q50616840 | Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia. |
| Q35813662 | Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report |
| Q21284676 | Second-generation antipsychotics and extrapyramidal adverse effects |
| Q48035618 | Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder |
| Q64070176 | Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin |
| Q36508056 | Tardive dyskinesia and essential fatty acids |
| Q34388086 | Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics |
| Q41903201 | Tardive dyskinesia with clozapine dose reduction or withdrawal dyskinesia? |
| Q36599203 | Tardive dyskinesia: treatment with aripiprazole |
| Q37445011 | The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism |
| Q64106835 | The use of clozapine and clonazepam co-administration in the treatment of a severe tardive dyskinesia: A case report |
| Q34823805 | Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges |
| Q37198420 | Treatment of neurolept-induced tardive dyskinesia |
| Q43261935 | Treatment of tardive dyskinesia with aripiprazole |
| Q34541147 | Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs |
| Q38789841 | Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? |
| Q57811016 | [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia] |
Search more.